Literature DB >> 14617549

Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease.

N A Chung1, C Lydakis, F Belgore, F L Li-Saw-Hee, A D Blann, G Y H Lip.   

Abstract

BACKGROUND: Thrombogenesis, angiogenesis, and endothelial damage/dysfunction are components in the pathogenesis of atherosclerosis.
OBJECTIVE: To investigate the relation of these variables to atherosclerotic disease severity and the possible interrelations between the three.
METHODS: 111 patients attending for coronary angiography were studied (85 male, 26 female; mean (SD) age, 61.6 (10.0) years). Plasma concentrations of von Willebrand factor (vWf, a marker of endothelial damage/dysfunction), vascular endothelial growth factor (VEGF, associated with angiogenesis), soluble VEGF receptor Flt-1 (sFlt-1), and tissue factor (TF, a key component of coagulation) were measured by an enzyme linked immunosorbent assay. Following angiography, disease severity was assessed by the number of coronary vessels diseased (> 50% stenosis) and by a coronary atheroma score.
RESULTS: All indices were raised in the patients compared with 34 healthy controls except sFlt-1, which was lower in the patients. No significant correlations were found between the coronary atheroma score and values of vWf (Spearman correlations: r = 0.21, p = 0.83), VEGF (r = 0.11, p = 0.27), or TF (r = -0.04, p = 0.68). However, there was an inverse correlation between plasma sFlt-1 and coronary atheroma score (r = -0.19, p = 0.049). The number of vessels diseased had no relation to any marker. Correlations were found between TF and VEGF (r = 0.25, p = 0.008) and between TF and sFlt-1 (r = 0.42, p < 0.001) in the patients.
CONCLUSIONS: Despite evidence of abnormal angiogenesis (VEGF and sFlt-1), thrombogenesis (TF), and endothelial damage/dysfunction (vWf) in the patients with coronary artery disease, there was no correlation between VEGF, sFlt-1, vWf, or TF and angiographically defined disease severity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14617549      PMCID: PMC1767979          DOI: 10.1136/heart.89.12.1411

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  35 in total

1.  Oxidative stress and increase of vascular endothelial growth factor in plasma of patients with peripheral arterial occlusive disease.

Authors:  R E Roller; W Renner; A Dorr; E Pilger; W J Schnedl
Journal:  Thromb Haemost       Date:  2001-02       Impact factor: 5.249

2.  Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension.

Authors:  F M Belgore; A D Blann; F L Li-Saw-Hee; D G Beevers; G Y Lip
Journal:  Am J Cardiol       Date:  2001-03-15       Impact factor: 2.778

3.  Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance.

Authors:  A Kranz; C Rau; M Kochs; J Waltenberger
Journal:  J Mol Cell Cardiol       Date:  2000-01       Impact factor: 5.000

4.  Expression of vascular endothelial growth factor in patients with acute myocardial infarction.

Authors:  Y Hojo; U Ikeda; Y Zhu; M Okada; S Ueno; H Arakawa; H Fujikawa; T Katsuki; K Shimada
Journal:  J Am Coll Cardiol       Date:  2000-03-15       Impact factor: 24.094

5.  Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.

Authors:  M Fleisch; M Billinger; F R Eberli; A R Garachemani; B Meier; C Seiler
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

6.  Intimal tissue factor activity is released from the arterial wall after injury.

Authors:  P L Giesen; B S Fyfe; J T Fallon; M Roque; M Mendlowitz; M Rossikhina; A Guha; J J Badimon; Y Nemerson; M B Taubman
Journal:  Thromb Haemost       Date:  2000-04       Impact factor: 5.249

7.  Increased blood vascular endothelial growth factor levels in patients with acute myocardial infarction.

Authors:  H Ogawa; H Suefuji; H Soejima; K Nishiyama; K Misumi; K Takazoe; S Miyamoto; I Kajiwara; H Sumida; T Sakamoto; M Yoshimura; K Kugiyama; H Yasue; K Matsuo
Journal:  Cardiology       Date:  2000       Impact factor: 1.869

8.  Serial changes in serum VEGF and HGF in patients with acute myocardial infarction.

Authors:  T Soeki; Y Tamura; H Shinohara; H Tanaka; K Bando; N Fukuda
Journal:  Cardiology       Date:  2000       Impact factor: 1.869

9.  Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with hypertension and patients with hypercholesterolemia.

Authors:  F M Belgore; G Y Lip; A D Blann
Journal:  Atherosclerosis       Date:  2000-08       Impact factor: 5.162

Review 10.  Gene targeting in hemostasis. tissue factor.

Authors:  N Mackman
Journal:  Front Biosci       Date:  2001-02-01
View more
  20 in total

1.  Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals.

Authors:  Allison C Ross; Suzanne Judd; Meena Kumari; Corrilynn Hileman; Norma Storer; Danielle Labbato; Vin Tangpricha; Grace A McComsey
Journal:  Antivir Ther       Date:  2011

2.  Animal model of left atrial thrombus in congestive heart failure in rats.

Authors:  Jiqiu Chen; Benjamin Strauss; Lifan Liang; Roger J Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-10       Impact factor: 4.733

3.  Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism.

Authors:  Jingjing Cai; Yuan Hong; Chunyan Weng; Chen Tan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-21       Impact factor: 4.733

4.  Short communication: initiation of an abacavir-containing regimen in HIV-infected adults is associated with a smaller decrease in inflammation and endothelial activation markers compared to non-abacavir-containing regimens.

Authors:  Corrilynn O Hileman; David A Wohl; Daniel J Tisch; Sara M Debanne; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-26       Impact factor: 2.205

5.  Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy.

Authors:  Allison C Ross; Rachel Armentrout; Mary Ann O'Riordan; Norma Storer; Nesrine Rizk; Danielle Harrill; Dalia El Bejjani; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

6.  A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

7.  Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.

Authors:  Allison C Ross; Nesrine Rizk; Mary Ann O'Riordan; Vikram Dogra; Dalia El-Bejjani; Norma Storer; Danielle Harrill; Marisa Tungsiripat; Jerome Adell; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2009-10-01       Impact factor: 9.079

8.  Pathway analysis of seven common diseases assessed by genome-wide association.

Authors:  Ali Torkamani; Eric J Topol; Nicholas J Schork
Journal:  Genomics       Date:  2008-09-16       Impact factor: 5.736

9.  T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early atherosclerosis.

Authors:  Esther Merlini; Kety Luzi; Elisa Suardi; Alessandra Barassi; Maddalena Cerrone; Javier Sánchez Martínez; Francesca Bai; Gian Vico Melzi D'Eril; Antonella D'Arminio Monforte; Giulia Marchetti
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

Review 10.  A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Christopher D Kontos; Brian H Annex; Aleksander S Popel
Journal:  J Cell Mol Med       Date:  2009-10-16       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.